126 related articles for article (PubMed ID: 10370788)
1. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD
Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
3. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
[TBL] [Abstract][Full Text] [Related]
5. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
6. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
7. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
10. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
11. Activity of oxaliplatin against human tumor colony-forming units.
Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
[TBL] [Abstract][Full Text] [Related]
12. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
13. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
14. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
[TBL] [Abstract][Full Text] [Related]
15. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Taveras AG; Kirschmeier P; Baum CM
Curr Top Med Chem; 2003; 3(10):1103-14. PubMed ID: 12769711
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
19. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
20. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.
Medina-Gundrum L; Cerna C; Gomez L; Izbicka E
Invest New Drugs; 2005 Jan; 23(1):3-9. PubMed ID: 15528975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
